ABBV ▲ +1.3% - AbbVie Inc. $ABBV AbbVie: Reports Strong Long-Term SKYRIZI and RINVOQ Remission Data in Inflammatory Bowel Disease at UEGW 2026 ? • SKYRIZI: Week 96 clinical remission of 54.0–73.1% and endoscopic remission of 38.8–53.5% in ulcerative colitis. • RINVOQ: Week 144 clinical remission of 78.9–86.6% and endoscopic remission of 47.1–64.2% in Crohn's disease. • Real-world RINVOQ data show 70.2% clinical response within 12 weeks, with median time to first response of 13 days. • AbbVie presents 20 scientific abstracts, including new data on investigational dual-targeting therapy ABBV-466. 17-OCT-2026 08:34 AM ET